HDM1005 demonstrates significantly enhanced potency over Tirzepatide, achieving 3-fold greater HbA1c reduction in diabetic mice and superior weight loss (39.97% versus 34.47%) in diet-induced obese models. The compound's engineered structure extends its half-life to 20.3-23.1 hours compared to Tirzepatide's 9.21 hours, potentially reducing injection frequency. This represents a meaningful advance in the rapidly evolving incretin therapy landscape, where GLP-1 receptor agonists like semaglutide and tirzepatide have already transformed diabetes and obesity treatment. The dual GLP-1/GIP mechanism targets complementary pathways for glucose regulation and satiety, potentially offering synergistic benefits. Particularly noteworthy is HDM1005's ability to preserve lean mass while promoting fat loss—a crucial advantage for sustainable weight management that addresses a key limitation of current therapies. However, these are preclinical mouse studies with inherent limitations in translating to human efficacy and safety. The compound's progression to human trials will determine whether this enhanced potency and duration translate to meaningful clinical advantages over existing incretin therapies in the competitive diabetes and obesity pharmaceutical market.